WCLC 2013:“watch and wait”模式是否可取?No

2013-11-08 广东省人民医院 周清 吴一龙 中国医学论坛报

尽管目前对晚期NSCLC已有多种治疗手段可采用,但是在实践中,确诊后没有立即接受治疗而采用“观察与等待(watch and wait,WW)”模式的现象仍广泛存在。会上,加拿大不列颠哥伦比亚省癌症治疗机构(BCCA)报告的一项回顾性研究结果回答了WW模式是否可取的问题。在694例晚期NSCLC患者中,46%立即接受了化疗,对24%采用WW,对30%采用最佳支持治疗(BSC)

尽管目前对晚期NSCLC已有多种治疗手段可采用,但是在实践中,确诊后没有立即接受治疗而采用“观察与等待(watch and wait,WW)”模式的现象仍广泛存在。

会上,加拿大不列颠哥伦比亚省癌症治疗机构(BCCA)报告的一项回顾性研究结果回答了WW模式是否可取的问题。在694例晚期NSCLC患者中,46%立即接受了化疗,对24%采用WW,对30%采用最佳支持治疗(BSC)。在WW组中,30%后续接受了化疗,但有43%错失了化疗时机。生存分析显示,立即接受化疗组的中位OS期是14.2个月,WW组是11.8个月,BSC组是4.4个月(P<0.0001)。研究结果提示,有相当大比例的患者因错失化疗机会而致生存期缩短,所以WW模式不可取。

点评 尽管本研究是回顾性研究,但其结论对于临床实践具有现实指导意义,也被选为WCLC新闻发布会内容之一。


版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1665362, encodeId=24761665362bf, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Mon Aug 11 04:05:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081939, encodeId=ac852081939c7, content=<a href='/topic/show?id=35032192c2' target=_blank style='color:#2F92EE;'>#AIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2192, encryptionId=35032192c2, topicName=AIT)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Jan 25 01:05:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412324, encodeId=b3911412324c9, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Sun Nov 10 02:05:00 CST 2013, time=2013-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602673, encodeId=106a16026e3f1, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Sun Nov 10 02:05:00 CST 2013, time=2013-11-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1665362, encodeId=24761665362bf, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Mon Aug 11 04:05:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081939, encodeId=ac852081939c7, content=<a href='/topic/show?id=35032192c2' target=_blank style='color:#2F92EE;'>#AIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2192, encryptionId=35032192c2, topicName=AIT)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Jan 25 01:05:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412324, encodeId=b3911412324c9, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Sun Nov 10 02:05:00 CST 2013, time=2013-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602673, encodeId=106a16026e3f1, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Sun Nov 10 02:05:00 CST 2013, time=2013-11-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1665362, encodeId=24761665362bf, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Mon Aug 11 04:05:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081939, encodeId=ac852081939c7, content=<a href='/topic/show?id=35032192c2' target=_blank style='color:#2F92EE;'>#AIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2192, encryptionId=35032192c2, topicName=AIT)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Jan 25 01:05:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412324, encodeId=b3911412324c9, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Sun Nov 10 02:05:00 CST 2013, time=2013-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602673, encodeId=106a16026e3f1, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Sun Nov 10 02:05:00 CST 2013, time=2013-11-10, status=1, ipAttribution=)]
    2013-11-10 木头人514
  4. [GetPortalCommentsPageByObjectIdResponse(id=1665362, encodeId=24761665362bf, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Mon Aug 11 04:05:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081939, encodeId=ac852081939c7, content=<a href='/topic/show?id=35032192c2' target=_blank style='color:#2F92EE;'>#AIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2192, encryptionId=35032192c2, topicName=AIT)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Jan 25 01:05:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412324, encodeId=b3911412324c9, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Sun Nov 10 02:05:00 CST 2013, time=2013-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602673, encodeId=106a16026e3f1, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Sun Nov 10 02:05:00 CST 2013, time=2013-11-10, status=1, ipAttribution=)]
    2013-11-10 bsmagic9138

相关威廉亚洲官网

第二届国际胸部肿瘤西子论坛召开

浙江大学附属第一医院胸外科、肺移植及胸部肿瘤科和呼吸疾病诊治中心主办的第二届国际胸部肿瘤西子论坛暨胸部微创新技术国家级继续教育学习班,第四届全国手汗症大会11月1-3日在浙江杭州召开。 随着胸腔镜技术的进步及设备的更新,以及对胸部疾病认识的进一步深入,目前胸部肿瘤的诊治已全面步入规范化、个体化及微创化时代。全胸腔镜肺癌根治(包括Uniport)、肺段切除、袖式切除、食管癌根治、肺小结

WCLC 2013:基于驱动基因分型的靶向治疗能显著改善生存

继美国临床肿瘤学会(ASCO)年会后,美国纪念斯隆-凯特林癌症中心的克里斯(Kris)教授代表肺癌突变协作组(LCMC)再次报道了该项目的进展。 LCMC项目自2009年立项以来在全美14家中心开展起来,这些中心具备检测10个驱动基因变异的能力,依据患者基因变异状态进行靶向治疗并将其分配到临床药物试验中。1007例患者提供了肿瘤组织标本,其中733例样本获得10个基因的检测结果,包括60

WCLC 2013:新型抑制剂治疗克唑替尼失败后 ALK阳性晚期NSCLC

ALK融合基因在非小细胞肺癌(NSCLC)的发生率约占3%~7%,ALK阳性晚期NSCLC患者对ALK抑制剂克唑替尼治疗有效,中位有效期约10个月。与其他分子靶向药物类似,克唑替尼治疗后患者不可避免地发生耐药,如何克服克唑替尼耐药性是临床上很棘手的难题。CH5424802是一种药效与特异性都更强的ALK抑制剂,有望克服ALK基因重排阳性晚期NSCLC患者接受克唑替尼治疗后发生的耐药性。

WCLC 2013:二线治疗是否必须基于驱动基因状态?Yes

在靶向治疗研究开展得如火如荼的今天,化疗领域的研究进展的确不够吸引眼球。然而,一项中国大陆开展的Ⅱ期多中心临床研究不仅作为2013年世界肺癌大会(WCLC)的口头发言,还被选入WCLC的新闻发布会,引起诸多关注,这就是中国胸部肿瘤研究协作组(CTONG)开展的CTONG 0806研究。 CTONG 0806研究是在EGFR野生型晚期非鳞癌非小细胞肺癌(NSCLC)中二

姜格宁:持续N2非小细胞肺癌可切除类型

在11月2日召开的第二届国际胸部肿瘤西子论坛上,上海肺科医院胸外科主任姜格宁针对持续N2非小细胞肺癌外科手术是否获益做了报告。 非小细胞肺癌(NSCLC)约占肺癌总数80%-85%,大约45%-50%为N2肺癌(ⅢA-N2肺癌)。 从临床治疗的角度,ⅢA-N2 NSCLC可分为可切除和不可切除两类。可切除的ⅢA-N2 NSCLC包括:ⅢA1:即切除标本最后病理学